Wróblewska JP, Dias-Santagata D, Ustaszewski A, et al: Prognostic roles of BRAF, KIT, NRAS, IGF2R and SF3B1 mutations in mucosal melanomas. Cells 10:2216, 2021. Crossref. PubMed. Google Scholar. 13.

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group.. It's ...

Conclusions: Baseline serum TKa levels efficiently predicted the outcome of patients with BRAF V600 mutated metastatic melanoma treated with different sequences of ICI and BRAF+MEK inhibitors.

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural changes that enable the BRAF protein to escape control and mimic its ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated ...

NEW YORK, May 30, 2025--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ...

A BRAF inhibitor–based regimen was given as subsequent therapy to 71.9% of the 139 patients in the standard-of-care arm who received additional treatment. The median time to second disease progression ...

To put it simply, the Breakwater results are “the first promising survival outcomes ever reported for BRAF-mutant metastatic colorectal cancer in the first-line setting, representing a practice ...

Despite the high unmet need in BRAF V600E-mutant mCRC, prior to December 20, 2024, there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF ...